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Theophylline, in addition to its bronchodilator effect, is re-
ported to have an antiinflammatory action that may ac-
count for its clinical effectiveness in the reduction of inflam-
matory cells in the airway. In bronchial asthma, such
inflammatory cytokines as GM-CSF and IL-5 are upregu-
lated and have been proposed to cause granulocyte infiltra-
tion (neutrophils and eosinophils) in the airway by inhibi-
tion of granulocyte apoptosis. We examined the abilities of
theophylline to counteract the prolongation of human gran-
ulocyte survival caused by cytokines. Theophylline was
shown to shorten granulocyte survival in a dose-dependent
manner. Upon incubation with a therapeutical concentra-




































0.02; 24-h incubation) in eosino-
phils. The percentage of IL-5 (5 ng/ml)–induced delayed















0.05). In contrast, cyclic AMP (cAMP)–increasing
agents (3-isobutylmethylxanthine, dibutyryl cAMP, and ro-
lipram) inhibited granulocyte apoptosis in the control and





-2 protein decreased after incubation with the-
ophylline. These findings suggest that theophylline acceler-
ates granulocyte apoptosis, which may play an essential role
in inflammation, and controls granulocyte longevity regard-






























Apoptosis, programmed cell death, is a physiologic suicide
mechanism that maintains cellular homeostasis in a variety of
tissues by removing unwanted cells (1). Accumulating evi-
dence indicates that the Fas (APO-1; CD95)/Fas ligand system
is an important cellular pathway responsible for the induction
of apoptosis in diverse tissues (2–4). 
Granulocytes (neutrophils and eosinophils) play important
roles at inflammatory sites due to bacterial or helminth infec-
tions and allergic diseases. The removal of these cells from the
inflamed site inhibits tissue damage by activated granulocytes
in normal nonpathogenic situations, and thus it is a critical
event in the regulation of granulocyte function. Fas is ex-
pressed on the surface of mature human granulocytes and is
capable of inducing rapid apoptosis, which suggests that the
Fas pathway may represent a fundamental mechanism for the
regulation of granulocyte apoptosis (5–7). 
 The unnecessary prolongation of granulocyte life and aug-
mentation of bactericidal ability may produce toxic substances
such as leukotriene and superoxide (8). GM-CSF extends the
life of neutrophils and eosinophils (9, 10), and administration
of GM-CSF is known to augment granulocyte function and
cause side effects such as systemic responses, including shock,
hypoxia, liver dysfunction, and respiratory distress (11, 12).
The regulation of granulocyte apoptosis has been proposed as
a key mechanism for the inhibition of inflammatory disease
and tissue damage.
 Theophylline, a methylxanthine derivative and nonspecific
phosphodiesterase inhibitor that has bronchodilator effects,
has been used in the treatment of bronchial asthma and has
only recently been considered as a potential antiinflammatory
agent. The inhibition of late asthmatic responses by theophyl-
line has been demonstrated in relation to the regulation of the
influx and activity of granulocytes (neutrophils and eosino-
phils) (13, 14). These effects of theophylline occur at serum
concentrations within the accepted therapeutic range (14).
 The present study was undertaken to evaluate the effects
of theophylline on the apoptosis of granulocytes induced by
anti–Fas antibody and to determine what mechanism underlies
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phosphodiesterase inhibitor), DMSO, and Hepes were purchased
from Sigma Chemical Co. (St. Louis, MO). A specific phosphodi-
esterase IV inhibitor (Rolipram; ME3167) was a gift from Meiji Seika
Kaisha (Kawasaki, Japan). Recombinant human GM-CSF (rhGM-
CSF) was supplied by Kirin Brewery (Tokyo, Japan) and human IL-5
was purchased from Genzyme Corp. (Cambridge, MA). IgM anti–Fas
antibody (CH11), FITC-labeled anti–Fas monoclonal antibody, and





-2 (clone 124) was from Dako Japan
(Kyoto, Japan). Anti–CD16 mAb-coated immunologic magnetic
beads and the magnetic cell sorter system were purchased from
Miltenyi Biotec Inc. (Bergisch Gladbach, Germany). 
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 Heparinized venous blood was obtained
from healthy volunteers. Neutrophils were isolated by dextran sedi-
mentation and centrifugation on a Histopaque gradient (without en-
dotoxin; Sigma Chemical Co.) as previously described (15). Contami-
nating red blood cells were removed by cold hypotonic water lysis.
Cells were then subjected to another density cut using centrifugation
over a Percoll gradient in order to isolate neutrophils from contami-
nating eosinophils. Eosinophils were purified from peripheral blood
of slightly allergic donors (mild rhinitis), using gradient centrifugation
and negative selection with anti–CD16 mAb-coated immunologic
magnetic beads and a magnetic cell sorter. The purity of the isolate
was assessed by preparing cytocentrifuged smears and staining with
May-Grünwald-Giemsa (Merck Ltd, Darmstadt, Germany) stain.









99%, as determined by trypan blue





smears were prepared from cells incubated in HBSS buffered with 10












 in order to prevent
clotting. The cells were incubated in the presence or absence of anti–
Fas antibody (CH11). The percentage of apoptotic cells was deter-
mined from 500-cell counts by two observers. Apoptotic cells were
Figure 1. Morphologic features of neutrophils (A–C) and eosinophils (D–F) incubated with 1 mg/ml CH11 (anti–Fas antibody) and theophylline 
(1 mM). May-Grünwald-Giemsa–stained preparations were photographed at 1,0003. Each granulocyte population was incubated for 9 h in the 






identified by characteristic chromatin condensation, cytoplasmic vac-
uolization, and formation of apoptotic bodies.
 










 cells were lysed by incubation








HCl, pH 7.4, 0.2







. The supernatant was extracted with chloroform/
isoamyl alcohol/phenol, and the aqueous phase was collected. The
DNA was precipitated with 50% 2-propranolol and 0.5 M sodium ac-


















samples were electrophoresed through a 1.2% agarose gel and








 To determine Fas expres-














-2, cells were fixed and permeabilized with Ortho Per-
meafix (Ortho Diagnostic Systems Inc., Raritan, NJ) for 40 min at





by immediate addition of FITC-conjugated antibody and further in-




C. The cells were resuspended in ice-cold



































 As shown in Fig. 1,





of anti–Fas antibody (CH11) for the indicated times, and
stained with May-Grünwald-Giemsa stain. At the light micro-
scopic level, the treated neutrophils demonstrated the charac-









, eosinophils with CH11 for 24 h): one or
a few darkly stained pyknotic nuclei, compacted but structur-
ally intact cytoplasmic organelles, and cytoplasm vacuolation
























































0.01; 24-h incubation). Thus, apoptosis was induced in both
granulocyte populations due to the treatment with anti–Fas
antibody.
 
Effects of theophylline, IBMX, rolipram, and dibutyryl cy-
clic AMP on granulocyte apoptosis.
 
 Theophylline, IBMX, ro-
lipram, and dibutyryl cyclic AMP (cAMP) were diluted in di-








C. The cells were exposed
to no more than 0.1% dimethyl sulfoxide. As shown in Fig. 3,
granulocytes were cocultured with theophylline, IBMX, roli-
pram, or dibutyryl cAMP at various concentrations. At the time
intervals, the proportion of apoptotic cells was assessed mor-
phologically. The addition of IBMX, rolipram (specific phospho-
diesterase inhibitors), or dibutyryl cAMP to the granulocytes
resulted in a concentration-dependent inhibition of granulo-
cyte apoptosis. Specially, upon addition of 1 mM IBMX, the
percentage of apoptotic cells in the control neutrophil and









































spectively. Under the same conditions, the percentage of apop-
totic cells in the CH11-treated neutrophil and eosinophil was












































addition of rolipram or dibutyryl cAMP also significantly re-







0.05). In contrast, theophylline caused signif-
icant induction of apoptosis of both cell types upon addition of
1 mM theophylline, the percentage of apoptotic cells in the









































4), respectively. The percentage of apoptotic cells in





























n 5 4), respectively. The morphological results are shown in
Fig. 1, C and F. At a therapeutic concentration (0.1 mM), the
percentage of apoptotic cells significantly increased in the con-
trol neutrophils and eosinophils (Fig. 3, A and B). 
Cellular apoptosis induced by anti–Fas antibody was con-
firmed by electrophoresis (Fig. 4). Agarose gel electrophoresis
of DNA from the granulocytes showed characteristic ladder-
like apoptotic patterns (DNA degradation). The augmentation
of laddering of DNA extracts by theophylline, and the inhibi-
tion by IBMX and dibutyryl cAMP is clearly visible in Fig. 4.
Effects of theophylline on GM-CSF– or IL-5–induced de-
layed granulocyte apoptosis.  When neutrophils and eosino-
phils were incubated with GM-CSF (10 ng/ml; 45 pM), the
percentage of apoptotic cells dramatically decreased. After in-
cubation for 9 h with CH11 (1 mg/ml), approximately 80% of
the neutrophils exhibited apoptotic characteristics. GM-CSF
markedly prevented anti–Fas antibody-induced neutrophil
apoptosis (from 78 to 18%; Fig. 5). When eosinophils were
incubated for 24 h, GM-CSF or IL-5 (5 ng/ml) inhibited
CH11-induced eosinophil apoptosis (from 47 to 21 or 22%;
Fig. 5) after the interval. Theophylline resulted in a concen-
tration-dependent increase in granulocyte apoptosis. Upon






were treated for vari-
ous time periods with 
(m) or without (d)
1 mg/ml anti–Fas anti-
body. Percentages of 




Data represent the 
mean6SD of four sep-
arate determinations.
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mM; 18 mg/ml), the percentage of apoptotic cells significantly
increased from 1862% to 3863% (n 5 4, P , 0.02) in the neu-
trophils and from 2162% to 3562% (n 5 4, P , 0.02) in the
eosinophils incubated with GM-CSF. Theophylline (0.1 mM)
also increased the percentage of the apoptotic eosinophils incu-
bated with IL-5 from 2264% to 3362% (n 5 4, P , 0.05). 
Granulocytes were treated with theophylline (0.05 mM; 9
mg/ml) at 378C for various time periods in the presence of GM-
CSF (10 ng/ml) (Fig. 6). Long incubation periods with the-
ophylline at the lower concentration significantly reduced the
viability of both neutrophils and eosinophils. 
Surface expression of Fas.  Cell surface expression of Fas
was detected on the control neutrophils by direct immunofluo-
rescence flow cytometry using FITC-conjugated mAb (Fig. 7).
Mean fluorescence intensity did not change after incubation
with 1 mM IBMX, dibutyryl cAMP, or theophylline for 8 h.
Because bcl-2 expression is known to counteract apoptosis,
flow cytometry was used to analyze the expression of bcl-2
protein by eosinophils. Fig. 8 shows that theophylline (0.1 mM)
reduced the expression of bcl-2 by eosinophils incubated for 72 h
in HBSS. 
Discussion
Human neutrophils and eosinophils are known to play crucial
roles at inflammatory sites. An abundance of evidence has es-
tablished the key regulatory role of these cells in inflammation
and host immune responses. Several inflammatory cytokines
including GM-CSF, IL-3, and IL-5 are reported to support the
survival and the activation of these cells (16–18). Fas antigen
or apoptosis antigen-1 (APO-1; CD95), a member of the tu-
mor necrosis factor/nerve growth factor receptor family, is ca-
pable of inducing apoptosis in susceptible cell populations (2,
3). The finding that human peripheral blood neutrophils and
eosinophils express functional Fas antigen suggests that this
molecule may also be involved in the regulation of inflamma-
tory disease (5–7, 19). The Fas–Fas ligand system in vivo is rec-
ognized as a mechanism to remove unwanted cells in the hu-
man body (2, 3, 19). Therefore, we hypothesized that a variety
of inflammatory cytokines (GM-CSF, IL-3, IL-5) augment
granulocyte development and survival (5 inflammation) and
that the Fas–Fas ligand system inhibits and regulates these cell
populations.
Figure 3. Effect of IBMX, rolipram, 
dibutyryl cAMP, and theophylline 
on granulocyte apoptosis. Neutro-
phils (A) were incubated for 9 h and 
eosinophils (B) for 24 h, and per-
centages of apoptotic cells were esti-
mated morphologically. Dark col-
umns represent data of cells treated 
with 1 mg/ml CH11 (anti–Fas anti-
body) and open columns represent 
data of nontreated cells. Data repre-
sent the mean6SD of four separate 
determinations. *P , 0.05 compared 
with no stimulus controls by t test.
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 Theophylline has been used worldwide for the treatment
of bronchial asthma (20, 21) and is currently being reevaluated
as an antiinflammatory agent. Persistent inflammation in the
airways is thought to be an essential feature of chronic asthma.
Inflammatory cell infiltrate exists in the airway walls even in
mild asthma. Theophylline is known to inhibit the activity of
immunocompetent cells (22). Furthermore, bronchoscopic
studies have revealed that oral theophylline therapy prevents
the late asthmatic reaction and causes significant reduction in
the number of granulocytes in the airway (14, 23). This phe-
nomenon may be regulated by apoptosis. The findings of the
present study show that, in vitro, theophylline significantly
shortened granulocyte survival in a dose-dependent manner
by accelerating apoptosis. Theophylline accelerated not only
Fas antibody-induced granulocyte apoptosis, but also the cells’
death without treatment with the antibody. In both neutro-
phils and eosinophils, these effects were not significant when
Figure 3 (Continued)
Figure 4. Agarose gel electrophoresis of DNA extracted from neu-
trophils after culture for 9 h under various conditions: (lane S) molec-
ular weight markers, (lane 1) control neutrophils, (lane 2) neutrophils 
with 1 mM IBMX, (lane 3) neutrophils with 1 mM theophylline, (lane 
4) neutrophils with 1 mM dibutyryl cAMP, (lane 5) neutrophils with 1 
mg/ml anti–Fas Ab, (lane 6) neutrophils with Ab and 1 mM IBMX, 
(lane 7) neutrophils with Ab and 1 mM theophylline, (lane 8) neutro-
phils with Ab and 1 mM dibutyryl cAMP. Representative data is 
shown.
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therapeutic levels of theophylline were used. However, the-
ophylline significantly prevented GM-CSF–mediated prolonged
survival of both neutrophils and eosinophils at therapeutical
level (0.1 mM). Furthermore, theophylline inhibited IL-5–
mediated eosinophil survival. These effects were observed at a
lower theophylline concentration (0.05 mM; 9 mg/ml) for
longer periods of incubation. Thus, the acceleration of granu-
locyte apoptosis by theophylline seems to be associated with
the inhibition of inflammation in the human body. 
 One possible explanation of the mechanism of antiinflam-
matory effect of theophylline is outlined below. Theophylline
is known to inhibit the activation of neutrophils and eosino-
phils. This agent inhibits the superoxide production induced by
a chemoattractant (24). cAMP-elevating agents (IBMX, for-
skolin, dibutyryl cAMP) and theophylline modulate chemoat-
tractant-induced phosphatidyl inositol 3-kinase, phospholipase
D activation, and inhibit granulocyte functions (25–27). The-
ophylline works as a cAMP-increasing agent (a phosphodi-
esterase inhibitor) in this phenomenon (24, 26). Cyclic AMP
alters the microfilament components of the actin cytoskeleton
(28) and influences the phosphorylation of Rap protein re-
quired for the activation of NADPH oxidase (29). This inhibi-
tory effect of theophylline on superoxide production by granu-
locytes was believed to be antiinflammatory (30, 31). 
 In contrast, the effect of theophylline on granulocyte apop-
tosis is quite different from that of other cAMP-increasing
agents (IBMX, rolipram, and dibutyryl cAMP). As deter-
mined in the present study, IBMX, rolipram (specific phos-
phodiesterase inhibitors), and dibutyryl cAMP delayed granu-
locyte apoptosis in the control and anti–Fas antibody-treated
cells, whereas theophylline accelerated granulocyte apoptosis.
This is consistent with previous observations (32). Pentoxifyl-
line, a methylxanthine derivative, is known to modulate neu-
trophil functions (33) and has been recently reported to inhibit
neutrophil apoptosis (34). Theophylline’s effect on granulo-
cyte apoptosis is quite different from that of other xanthine de-
rivatives. 
 Theophylline had no effect on cell surface Fas expression.
Bcl-2 is known to be an important gene involved in suppres-
sion of apoptosis, and overexpression of bcl-2 protein has been
found to protect cells against several apoptotic stimuli (35).
Mentz et al. (36) recently reported that theophylline can in-
duce apoptosis in malignant B cells, and the drug downregu-
lates the expression of bcl-2 protein. The results of the present
study indicate that theophylline downregulates the expression
of bcl-2 protein in eosinophils and may induce apoptosis. As
neutrophils are essentially absent of bcl-2 expression (5) and
many genes and proteins are involved in the induction or sup-
pression of apoptosis, this notion cannot be proven beyond
doubt. However, our results provide evidence that theophyl-
line accelerates human eosinophil apoptosis, at least in part, by
suppression of bcl-2 protein. 
Figure 5. Effects of 
theophylline on GM-
CSF– or IL-5–induced 
delayed apoptosis of 
granulocytes. Neutro-
phils were incubated 
with GM-CSF (10 ng/
ml) and CH11 (1 mg/ml) 
for 9 h, and eosinophils 
were incubated with 
GM-CSF or IL-5 (5 ng/
ml) and CH11 for 24 h. 
Dark columns represent 
data without GM-CSF 
or IL-5, open columns
represent data with 
GM-CSF or IL-5.
Values represent the 
mean6SD of four sepa-
rate determinations.
*P , 0.05 and **P , 
0.02 compared with no 
theophylline controls by 
t test.
Figure 6. Time-depen-
dent induction of apop-
totic granulocytes. 
Cells were treated for 
various time periods 
with 1 mg/ml anti–Fas 
antibody. Cells were 
incubated with (m and 
j) or without (s) 
GM-CSF (10 ng/ml). 
Effects of theophylline 
(0.05 mM; 9 mg/ml) 
were also determined 
(m). Values represent 
the mean6SD of three 
separate determina-
tions. *P , 0.05 and 
**P , 0.02 compared 
with no theophylline 
controls by t test.
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Figure 8. Bcl-2 expression of eosinophils incubated 
in HBSS for 72 h (hatched area). Isotype-matched 
negative control mAb is indicated by dotted line. 
Cells were incubated with theophylline (0.1 mM), 
GM-CSF (10 ng/ml), or dibutyryl cAMP (1 mM). 
Data of control cells incubated in HBSS are indicated 
by bold line. Representative data is shown.
